Catalyst
Slingshot members are tracking this event:
BioCryst (BCRX) Phase 2 APEX-1 Data Evaluating Killikrein Inhibitor BCX7353 in Reducing Frequency of Attacks in Patients with Hereditary Angioedema (HAE)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BCRX |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Apex-1, Killikrein Inhibitor, Bcx7353, Reducing Frequency, Hereditary Angioedema, Hae